Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of benralizumab on small airways

Next Previous
Trial Profile

The effect of benralizumab on small airways

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms TBA

Most Recent Events

  • 13 Sep 2023 Status changed from not yet recruiting to active, no longer recruiting, according to results presented at the 33rd Annual Congress of the European Respiratory Society.
  • 13 Sep 2023 Primary endpoint (FRI based SAD, defined as change in specific image-based airway volume (SIVAW)) has been met, according to a results presented at the 33rd Annual Congress of the European Respiratory Society.
  • 30 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top